Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

BioArctic AB (publ)

Healthcare US BRCTF

35.0USD
0.00(0%)

Last update at 2026-06-19T20:00:00Z

Day Range

35.0035.00
LowHigh

52 Week Range

17.9838.06
LowHigh

Fundamentals

  • Previous Close 35.00
  • Market Cap2926.94M
  • Volume250
  • P/E Ratio26.21
  • Dividend Yield-%
  • EBITDA1301.46M
  • Revenue TTM1916.31M
  • Revenue Per Share TTM21.64
  • Gross Profit TTM 1860.31M
  • Diluted EPS TTM1.26

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 1252.44M -189.51900M 276.49M -11.16700M -140.51100M
Minority interest - - - - -
Net income 1019.76M -177.07900M 229.25M -11.17900M -119.78900M
Selling general administrative 194.83M 93.38M - 30.58M 24.85M
Selling and marketing expenses - 55.46M - - -
Gross profit 1935.03M 230.37M 526.37M 153.97M -31.92100M
Reconciled depreciation - 10.72M 17.44M 14.18M 13.04M
Ebit 1364.71M -229.61800M 276.81M -10.60800M -139.67300M
Ebitda 1377.51M -211.19000M 295.24M 4.03M -126.56600M
Depreciation and amortization 12.80M 18.43M 18.43M 14.63M 13.11M
Non operating income net other - - - - -
Operating income 1364.71M -228.51400M 252.64M -17.44200M -139.72300M
Other operating expenses 629.39M 485.87M 363.36M 236.23M 163.00M
Interest expense 37.81M 1.85M 0.38M 0.56M 0.84M
Tax provision 233.26M -12.44000M 35.65M 0.01M -20.72300M
Interest income 34.68M 40.84M 20.66M 2.54M 0.07M
Net interest income -3.22200M 39.00M 18.94M 1.78M -0.98300M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 232.68M -12.44000M 47.24M 0.01M -20.72300M
Total revenue 1994.10M 257.35M 616.00M 228.29M 23.15M
Total operating expenses 570.32M 458.88M 273.73M 161.90M 107.93M
Cost of revenue 59.07M 26.98M 89.63M 74.33M 55.07M
Total other income expense net -112.27564M 38.99M 23.85M 6.17M -0.78800M
Discontinued operations - - - - -
Net income from continuing ops 1022.32M -177.07900M 258.62M -11.17800M -119.78900M
Net income applicable to common shares - - - -11.17900M -119.78900M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2568.77M 1111.68M 1186.08M 858.31M 897.73M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 295.78M 160.55M 40.95M 15.45M -0.00100M
Total liab 606.62M 216.74M 139.50M 72.06M 109.05M
Total stockholder equity 1962.15M 894.94M 1046.58M 786.24M 788.68M
Deferred long term liab - - - - -
Other current liab 333.22M 112.06M 58.51M 5.43M 63.04M
Common stock 1.77M 1.77M 1.77M 786.24M 1.76M
Capital stock - 1.77M 1.77M 1.76M 1.76M
Retained earnings - 305.11M 462.87M 217.52M 225.94M
Other liab - - - - 0.00100M
Good will - - - - -
Other assets - - 0.00100M 2.20M 2.20M
Cash 1037.82M 512.93M 611.57M 805.39M 848.40M
Cash and equivalents - - - - -
Total current liabilities 519.47M 175.66M 124.97M 70.88M 101.27M
Current deferred revenue - - 33.76M - -
Net debt -965.58373M -458.69900M -606.58800M - -
Short term debt 15.68M 13.15M 2.83M - -
Short long term debt - - - - -
Short long term debt total 72.24M 54.23M 4.98M - -
Other stockholder equity 1960.38M 587.10M 580.98M - 0.96M
Property plant equipment - - - 35.26M 33.75M
Total current assets 2480.72M 1010.66M 1152.74M 820.84M 861.79M
Long term investments - - - - -
Net tangible assets - - - 786.24M 788.68M
Short term investments 1147.12M 265.99M 500.00M - -
Net receivables - 71.20M 0.22M 0.00000M 9.04M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 170.57M 50.45M 29.87M 26.92M 11.82M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.96M 0.96M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00001M 3.44M 1.65M - 0.00100M
Deferred long term asset charges - - - - -
Non current assets total 88.05M 101.02M 33.34M 37.47M 35.94M
Capital lease obligations 44.07M 54.23M 4.98M 10.04M 15.88M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 205.63M -306.56000M -12.76300M -0.02700M
Change to liabilities - - - 0.00000M 0.00000M
Total cashflows from investing activities -892.40575M 205.63M - -12.76300M -4.41200M
Net borrowings - - - -2.80000M -7.38900M
Total cash from financing activities 26.84M 5.69M 14.06M -2.80800M -7.38900M
Change to operating activities - - - 24.91M 0.06M
Net income 1019.76M -228.51500M 252.64M -17.44200M -139.72300M
Change in cash 612.24M -98.64000M -193.81900M -43.01900M -151.53500M
Begin period cash flow 425.58M 611.57M 805.39M 848.40M 999.94M
End period cash flow 1037.82M 512.93M 611.57M 805.39M 848.40M
Total cash from operating activities 1427.48M -316.33200M 309.69M -31.63800M -140.45700M
Issuance of capital stock - 6.02M 14.98M 5.99M 0.00000M
Depreciation 12.80M 10.72M 7.44M 14.18M 13.04M
Other cashflows from investing activities -892.40575M 205.63M - 0.04M 0.00100M
Dividends paid - - - - -
Change to inventory - - -14.41500M - -
Change to account receivables -64.60751M -105.22500M -11.97900M -0.23054M -0.56393M
Sale purchase of stock - - - - -
Other cashflows from financing activities 26.84M -0.00100M -0.91800M -8.79300M -7.38900M
Change to netincome - - - -60.00600M -29.12800M
Capital expenditures 1427.48M 26.64M 7.44M 12.75M 4.39M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 173.78M -62.57000M 13.15M 24.91M -5.06000M
Stock based compensation - 19.33M 16.14M 2.76M 1.57M
Other non cash items 221.14M -25.24700M 20.32M -58.47800M -8.46600M
Free cash flow 1431.07M -342.96700M 302.25M -44.38400M -144.84300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BRCTF
BioArctic AB (publ)		 - -% 35.00 26.21 357.14 13.44 13.64 13.54 20.93
NVO
Novo Nordisk A/S		 2.94 6.80% 46.12 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.54 2.78% 464.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -1.76 0.29% 608.18 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.

BioArctic AB (publ)

Warfvinges vag 35, Stockholm, Sweden, 112 51

Key Executives

Name Title Year Born
Dr. Gunilla Osswald Ph.D. Chief Exec. Officer 1961
Dr. Pär Gellerfors Co-Founder, Sr. VP of Bus. Strategy & Director 1947
Prof. Lars Lannfelt Co-Founder, Sr. VP of University Collaborations & Director 1949
Mr. Jan Mattsson VP of Fin., Sec. of the Board & CFO 1960
Mr. Christer Möller VP of Pre-Clinical Devel. & Chief Scientific Officer 1959
Mr. Oskar Bosson VP of Communications & IR 1976
Mr. Harald Borgeke Head of Public Affairs NA
Ms. Frida Lekander Head of Marketing NA
Ms. Gunilla Andersson Sr. Director of HR 1961
Ms. Johanna Fälting VP & Head of Research 1972

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.